Form 4: UTHR CFO Edgemond Exercises Options, Sells Shares

United Therapeutics CFO James Edgemond exercised stock options and sold a portion of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), executed transactions on March 23, 2026.
• Exercised 10,000 stock options at an exercise price of $135.42 per share.
• Sold a total of 9,375 shares of common stock at weighted average prices ranging from $518.283 to $536.275.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on October 31, 2025.
• Following these transactions, Edgemond directly beneficially owns 18,876 shares of common stock.
• Edgemond also holds 152,500 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a pre-planned 10b5-1 plan mitigates concerns about opportunistic selling based on non-public information.

Positives

• The exercise of stock options indicates the reporting person is realizing value from their compensation, which can be a sign of confidence in the company's long-term performance.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information.

Negatives

• The sale of 9,375 shares by a key executive could be perceived negatively by some investors, as it reduces their direct equity stake in the company.

Industry Context

StockSavvy.ai notes that insider transactions, such as option exercises and subsequent sales, are common events in the biotechnology and pharmaceutical industry, often reflecting executives managing their personal portfolios and liquidity needs, especially when executed under pre-arranged 10b5-1 plans.

Comparison to Industry Standards

• StockSavvy.ai observes that the execution of stock options and subsequent sales by executives is a standard practice across industries, including biotech, for managing long-term incentive compensation.
• While specific comparable companies or projects are not relevant for this type of filing, the use of a 10b5-1 plan aligns with best practices for insider trading compliance, similar to executives at companies like Pfizer or Johnson & Johnson who routinely use such plans for equity transactions.

Related Party Transactions

• The transactions involve the CFO of United Therapeutics Corp exercising stock options and selling company shares, which is a direct related party transaction as defined by SEC regulations for insider reporting.

Stakeholder Impact

• Shareholders may view the sale of shares by a key executive with slight caution, though the 10b5-1 plan context reduces concerns about negative implications.
• Employees are unlikely to be directly impacted by this executive's personal trading activity.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and subsequent sale) executed under a pre-established 10b5-1 plan. This type of transaction is generally not indicative of new fundamental information about the company's prospects. Therefore, it does not provide a basis for a change in investment recommendation, suggesting a 'hold' position for investors based solely on this filing.

Keywords

United Therapeutics, UTHR, James Edgemond, CFO, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Executive Compensation